GSA Capital Partners LLP Acquires Shares of 5,081 Novartis AG (NVS)

GSA Capital Partners LLP acquired a new stake in Novartis AG (NYSE:NVS) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,081 shares of the company’s stock, valued at approximately $424,000.

Other hedge funds also recently modified their holdings of the company. City Holding Co. raised its stake in shares of Novartis AG by 4.6% in the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after acquiring an additional 54 shares in the last quarter. Archford Capital Strategies LLC grew its holdings in Novartis AG by 72.3% in the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after buying an additional 621 shares during the last quarter. Kernodle & Katon Asset Management Group LLC grew its holdings in Novartis AG by 3.4% in the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares during the last quarter. Massey Quick & Co. LLC acquired a new stake in Novartis AG in the 1st quarter valued at approximately $119,000. Finally, North Star Investment Management Corp. grew its holdings in Novartis AG by 1.0% in the 2nd quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after buying an additional 16 shares during the last quarter. 10.92% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have issued reports on the company. Leerink Swann reaffirmed a “market perform” rating and issued a $83.00 target price on shares of Novartis AG in a report on Thursday, June 22nd. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, September 26th. Zacks Investment Research lowered Novartis AG from a “buy” rating to a “hold” rating in a report on Thursday, September 21st. BidaskClub raised Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Finally, Morgan Stanley raised Novartis AG from an “underweight” rating to an “overweight” rating in a report on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. Novartis AG presently has a consensus rating of “Hold” and an average target price of $84.13.

Shares of Novartis AG (NVS) opened at 85.99 on Friday. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The firm has a market cap of $201.47 billion, a price-to-earnings ratio of 31.39 and a beta of 0.73. The firm has a 50-day moving average price of $85.15 and a 200-day moving average price of $81.72.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.23 earnings per share. Equities research analysts anticipate that Novartis AG will post $4.75 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “GSA Capital Partners LLP Acquires Shares of 5,081 Novartis AG (NVS)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/2956910/gsa-capital-partners-llp-acquires-shares-of-5081-novartis-ag-nvs.html.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.